MEDOPSIS Trademark

Trademark Overview

On Tuesday, May 10, 2022, a trademark application was filed for MEDOPSIS with the United States Patent and Trademark Office. The USPTO has given the MEDOPSIS trademark a serial number of 97403956. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, July 1, 2025. This trademark is owned by Medopsis Medical Technologies Inc.. The MEDOPSIS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development
medopsis

General Information

Serial Number97403956
Word MarkMEDOPSIS
Filing DateTuesday, May 10, 2022
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, July 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 31, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMedopsis Medical Technologies Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRichmond Hill, Ontario L4B1A3
CA

Trademark Events

Event DateEvent Description
Friday, May 13, 2022NEW APPLICATION ENTERED
Monday, May 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 27, 2023ASSIGNED TO EXAMINER
Tuesday, February 28, 2023NON-FINAL ACTION WRITTEN
Tuesday, February 28, 2023NON-FINAL ACTION E-MAILED
Tuesday, February 28, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 30, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 30, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 30, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 30, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 30, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 31, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 23, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, April 18, 2024SUSPENSION LETTER WRITTEN
Thursday, April 18, 2024LETTER OF SUSPENSION E-MAILED
Thursday, April 18, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, January 24, 2025INQUIRY TO SUSPENSION E-MAILED
Tuesday, June 27, 2023SUSPENSION LETTER WRITTEN
Tuesday, June 27, 2023LETTER OF SUSPENSION E-MAILED
Tuesday, June 27, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, December 28, 2023SUSPENSION INQUIRY WRITTEN
Thursday, December 28, 2023INQUIRY TO SUSPENSION E-MAILED
Thursday, December 28, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Friday, January 24, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Tuesday, July 1, 2025ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, July 1, 2025ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Friday, January 24, 2025SUSPENSION INQUIRY WRITTEN
Friday, January 24, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

Related Keywords

medopsis development research pharmaceutical